The World Market for Medicaments Containing Antibiotics (Except Penicillins and Streptomycins): A 2024 Global Trade Perspective
This report was created for strategic planners, international executives, and import/export managers who are concerned with the market for medicaments containing antibiotics (except penicillins and streptomycins) excluding those in dosage form or retail packings. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. Professor Philip M. Parker, the Chair Professor of Management Science at INSEAD, has developed a methodology, based on macroeconomic and trade models, to estimate the market for medicaments containing antibiotics (except penicillins and streptomycins) excluding those in dosage form or retail packings for those countries serving the world market via exports or supplying from various countries via imports. He does so for the current year based on a variety of key historical indicators and econometric models.
"Medicaments containing antibiotics (except penicillins and streptomycins) excluding those in dosage form or retail packings" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines "medicaments containing antibiotics (except penicillins and streptomycins) excluding those in dosage form or retail packings" is 54212.
- 1 METHODOLOGY
- 1.1 OUR APPROACH
- 2 THE WORLD MARKET
- 2.1 EXPORTS
- 2.1.1 THE WORLD MARKET: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS EXPORT SUPPLIES IN 2024
- 2.2 IMPORTS
- 2.2.1 THE WORLD MARKET: IMPORTED MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3 EXPORTS
- 3.1 AFRICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.1.1 EXECUTIVE SUMMARY
- 3.1.2 DJIBOUTI
- 3.1.3 EGYPT
- 3.1.4 GHANA
- 3.1.5 KENYA
- 3.1.6 MOROCCO
- 3.1.7 SOUTH AFRICA
- 3.1.8 TUNISIA
- 3.1.9 UGANDA
- 3.1.10 ZIMBABWE
- 3.2 ASIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.2.1 EXECUTIVE SUMMARY
- 3.2.2 BANGLADESH
- 3.2.3 CHINA
- 3.2.4 HONG KONG
- 3.2.5 INDIA
- 3.2.6 INDONESIA
- 3.2.7 JAPAN
- 3.2.8 MALAYSIA
- 3.2.9 SINGAPORE
- 3.2.10 SOUTH KOREA
- 3.2.11 TAIWAN
- 3.2.12 THAILAND
- 3.2.13 THE PHILIPPINES
- 3.2.14 VIETNAM
- 3.3 EUROPE: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.3.1 EXECUTIVE SUMMARY
- 3.3.2 AUSTRIA
- 3.3.3 BELGIUM
- 3.3.4 BULGARIA
- 3.3.5 CYPRUS
- 3.3.6 DENMARK
- 3.3.7 FRANCE
- 3.3.8 GERMANY
- 3.3.9 GREECE
- 3.3.10 HUNGARY
- 3.3.11 IRELAND
- 3.3.12 ITALY
- 3.3.13 LITHUANIA
- 3.3.14 MALTA
- 3.3.15 POLAND
- 3.3.16 PORTUGAL
- 3.3.17 ROMANIA
- 3.3.18 RUSSIA
- 3.3.19 SLOVAKIA
- 3.3.20 SLOVENIA
- 3.3.21 SPAIN
- 3.3.22 SWEDEN
- 3.3.23 SWITZERLAND
- 3.3.24 THE CZECH REPUBLIC
- 3.3.25 THE NETHERLANDS
- 3.3.26 THE UNITED KINGDOM
- 3.3.27 UKRAINE
- 3.4 LATIN AMERICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.4.1 EXECUTIVE SUMMARY
- 3.4.2 ARGENTINA
- 3.4.3 BRAZIL
- 3.4.4 COLOMBIA
- 3.4.5 ECUADOR
- 3.4.6 GUATEMALA
- 3.4.7 MEXICO
- 3.4.8 PANAMA
- 3.4.9 PERU
- 3.4.10 URUGUAY
- 3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.5.1 EXECUTIVE SUMMARY
- 3.5.2 CANADA
- 3.5.3 THE DOMINICAN REPUBLIC
- 3.5.4 THE UNITED STATES
- 3.6 OCEANIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.6.1 EXECUTIVE SUMMARY
- 3.6.2 AUSTRALIA
- 3.6.3 NEW ZEALAND
- 3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
- 3.7.1 EXECUTIVE SUMMARY
- 3.7.2 ISRAEL
- 3.7.3 JORDAN
- 3.7.4 SAUDI ARABIA
- 3.7.5 SYRIA
- 3.7.6 THE UNITED ARAB EMIRATES
- 3.7.7 TURKEY
- 4 IMPORTS
- 4.1 AFRICA: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.1.1 EXECUTIVE SUMMARY
- 4.1.2 ALGERIA
- 4.1.3 BENIN
- 4.1.4 BOTSWANA
- 4.1.5 BURUNDI
- 4.1.6 CAMEROON
- 4.1.7 COTE D'IVOIRE
- 4.1.8 EGYPT
- 4.1.9 ETHIOPIA
- 4.1.10 MALAWI
- 4.1.11 MAURITANIA
- 4.1.12 MOROCCO
- 4.1.13 MOZAMBIQUE
- 4.1.14 NAMIBIA
- 4.1.15 NIGERIA
- 4.1.16 RWANDA
- 4.1.17 SENEGAL
- 4.1.18 SOUTH AFRICA
- 4.1.19 TANZANIA
- 4.1.20 UGANDA
- 4.1.21 ZAMBIA
- 4.1.22 ZIMBABWE
- 4.2 ASIA: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.2.1 EXECUTIVE SUMMARY
- 4.2.2 BRUNEI
- 4.2.3 CHINA
- 4.2.4 HONG KONG
- 4.2.5 INDIA
- 4.2.6 INDONESIA
- 4.2.7 JAPAN
- 4.2.8 MALAYSIA
- 4.2.9 MONGOLIA
- 4.2.10 NEPAL
- 4.2.11 SINGAPORE
- 4.2.12 SOUTH KOREA
- 4.2.13 SRI LANKA
- 4.2.14 TAIWAN
- 4.2.15 THAILAND
- 4.2.16 THE PHILIPPINES
- 4.2.17 VIETNAM
- 4.3 EUROPE: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.3.1 EXECUTIVE SUMMARY
- 4.3.2 AUSTRIA
- 4.3.3 BELARUS
- 4.3.4 BELGIUM
- 4.3.5 BULGARIA
- 4.3.6 CYPRUS
- 4.3.7 DENMARK
- 4.3.8 ESTONIA
- 4.3.9 FINLAND
- 4.3.10 FRANCE
- 4.3.11 GERMANY
- 4.3.12 GREECE
- 4.3.13 HUNGARY
- 4.3.14 IRELAND
- 4.3.15 ITALY
- 4.3.16 KAZAKHSTAN
- 4.3.17 LATVIA
- 4.3.18 LUXEMBOURG
- 4.3.19 MOLDOVA
- 4.3.20 NORWAY
- 4.3.21 POLAND
- 4.3.22 PORTUGAL
- 4.3.23 ROMANIA
- 4.3.24 RUSSIA
- 4.3.25 SLOVAKIA
- 4.3.26 SLOVENIA
- 4.3.27 SPAIN
- 4.3.28 SWEDEN
- 4.3.29 SWITZERLAND
- 4.3.30 THE CZECH REPUBLIC
- 4.3.31 THE NETHERLANDS
- 4.3.32 THE UNITED KINGDOM
- 4.3.33 UKRAINE
- 4.4 LATIN AMERICA: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.4.1 EXECUTIVE SUMMARY
- 4.4.2 ARGENTINA
- 4.4.3 BRAZIL
- 4.4.4 CHILE
- 4.4.5 COLOMBIA
- 4.4.6 EL SALVADOR
- 4.4.7 GUATEMALA
- 4.4.8 GUYANA
- 4.4.9 HONDURAS
- 4.4.10 MEXICO
- 4.4.11 NICARAGUA
- 4.4.12 PANAMA
- 4.4.13 PARAGUAY
- 4.4.14 PERU
- 4.4.15 URUGUAY
- 4.5 NORTH AMERICA & THE CARIBBEAN: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.5.1 EXECUTIVE SUMMARY
- 4.5.2 CANADA
- 4.5.3 JAMAICA
- 4.5.4 THE UNITED STATES
- 4.6 OCEANIA: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.6.1 EXECUTIVE SUMMARY
- 4.6.2 AUSTRALIA
- 4.6.3 FRENCH POLYNESIA
- 4.6.4 NEW ZEALAND
- 4.6.5 PALAU
- 4.6.6 TONGA
- 4.7 THE MIDDLE EAST: MEDICAMENTS CONTAINING ANTIBIOTICS (EXCEPT PENICILLINS AND STREPTOMYCINS) EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
- 4.7.1 EXECUTIVE SUMMARY
- 4.7.2 ISRAEL
- 4.7.3 JORDAN
- 4.7.4 KUWAIT
- 4.7.5 OMAN
- 4.7.6 PAKISTAN
- 4.7.7 QATAR
- 4.7.8 TURKEY
- 4.7.9 YEMEN
- 5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
- 5.1 DISCLAIMERS & SAFE HARBOR
- 5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook